用MP-AzeFlu控制过敏性鼻炎:一项瑞典队列的非干预性研究
这项多中心、前瞻性、非干预性研究纳入431例12岁及以上中重度过敏性鼻炎患者,处方MP-AzeFlu后以视觉模拟量表(VAS)评估。VAS均值从基线67.9 mm降至最后一天32.1 mm,第3天84.0%患者报告症状良好或部分控制,结论认为MP-AzeFlu在真实世界中提供快速、有效且持久的症状控制。
要点
- VAS均值从基线67.9 mm降至最后一天32.1 mm。
- 第3天84.0%患者报告症状良好或部分控制。
- 第1、3、7天和最后一天达到38 mm及以上良好控制切点的比例分别为17.7%、32.2%、53.8%和64.2%。
核心结论
- MP-AzeFlu在瑞典真实世界环境中为过敏性鼻炎患者提供快速、有效且持久的症状控制,与欧盟和MACVIA-ARIA倡议一致,并支持MP-AzeFlu在真实生活中治疗过敏性鼻炎的有效性。
研究设计与样本
- 多中心、前瞻性、非干预性研究,纳入431例12岁及以上符合ARIA定义的中重度过敏性鼻炎患者并处方MP-AzeFlu。
主要发现
- MP-AzeFlu使VAS均值(标准差)从基线67.9(16.1)mm降至最后一天32.1(22.8)mm。
- 结果不受严重程度、表型、患者年龄组或既往治疗影响。
- 第3天84.0%患者报告症状良好或部分控制。
- 第1、3、7天和最后一天分别有17.7%、32.2%、53.8%和64.2%患者达到38 mm及以上的「良好控制」VAS切点。
关键数值与推荐
- VAS评分范围0(完全不困扰)至100 mm(非常困扰),于第0、1、3、7天及约14天后早晨使用MP-AzeFlu前评估。
- 第3天评估患者感知的疾病控制水平。
- 良好和部分控制过敏性鼻炎的VAS切点定义为38 mm及以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Union has prioritised allergic rhinitis (AR) control. A visual analogue scale (VAS) has been endorsed as the AR control language and embedded into the most recent MACVIA-ARIA guideline. This study assessed the effectiveness and safety of MP-AzeFlu using a VAS in a real-life study in Sweden. METHODS: 431 patients aged 12 years or over with ARIA-defined moderate to severe AR were included in this multicentre, prospective, non-interventional study and prescribed MP-AzeFlu. Patients assessed symptom severity using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) on Days 0, 1, 3 and 7, and after approximately 14 days in the morning before using MP-AzeFlu. Patients' perceived level of disease control was assessed on Day 3. The proportion of patients who achieved a defined VAS score cutoff for well- and partly controlled AR was also calculated. RESULTS: MP-AzeFlu reduced mean (SD) VAS score from 67.9 (16.1) mm at baseline to 32.1 (22.8) mm on the last day. Results were consistent irrespective of severity, phenotype, patient age class or previous treatment. By Day 3, 84.0% of patients reported well- or partly controlled symptoms. Overall, 17.7%, 32.2%, 53.8% and 64.2% of patients achieved a 38 mm or greater "well-controlled" VAS score cutoff on Day 1, 3 and 7 and last day, respectively. CONCLUSIONS: MP-AzeFlu provided rapid, effective and sustained symptom control in patients with AR from Sweden in a realworld setting, aligning with EU and MACVIA-ARIA initiatives and supporting the effectiveness of MP-AzeFlu for AR treatment in real life.
引用
- Stjarne P, Strand V, Theman K, et al. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology. 2019. PMID: 30938376. doi:10.4193/Rhin18.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。